GSK aids grassroots vaccination personnel in capacity-building

The National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission (hereinafter referred to as NHFPC), with the support of the China Centre for Disease Control and Prevention and the aid of GSK, was officially kicked off today. The programme kick-off ceremony was attended by leaders from authorities such as the Disease Control Bureau of the NHFPC, the China Centre for Disease Control and Prevention, and the Chinese Preventive Medicine Association. 

In the coming three years, over 4,000 grassroots vaccination personnel are expected to be trained by the programme, which covers the interpretation of the new vaccine distribution policies, vaccination practices and procedures, technical standards for the treatment of suspected adverse reactions during vaccination, etc. This programme is aiming to further promote the training of public-health and preventive-medicine personnel, improving overall level of prevention and vaccination, effectively curbing the outbreak of major disease epidemics. 

Mr. Tongling Jin, Director of the Disease Control Bureau, NHFPC, commented that changes have been made in the relative laws, regulations and procedures since last April. Overall, the policy framework is sound, the priority now is to implement all the policies, documents and requirements. The training kicked off today is one of the key actions to ensure the implementation in details. 

Mr. Weizhong Yang, Secretary-General of the Chinese Preventive Medicine Association, commented that the training programme received high attention and support from NHFPC, as well as funding support from socially responsible companies like GSK. The management and implementation of the programme would require joint efforts from all sides, to ensure administrative and technical requirements will be realised, for the programme to play an active role in the further standardisation of vaccination services. 

Grace Huang, General Manager, GSK China Vaccines said: "Through the kick-off of today’s project, we hope to cooperate more actively with the disease-control system to have a greater impact in terms of capacity-building. The new policies on vaccination will greatly enhance the development of vaccines market in China. Higher distribution efficiency and enhanced cold-chain logistics standards can be achieved due to simplified distribution procedures. Under the new policies, we will also continue to support professional academic training and exchanges, and play a positive role in further upgrading of prevention and vaccination level." 

Last year, the China State Council released a revised edition of its management guidelines for vaccine distribution and preventive vaccination. The revised edition has helped to enhance safety in the area of vaccine distribution as well as the conformity of vaccinations with standard procedures. GSK China is in full support of the implementation of the new policies, and in the spirit of new policies, has completed a series of internal reforms, including the re-structuring of supply chain, optimisation of processes, and strengthening of quality management. 


As part of the ‘in China, with China, for China’ strategy, GSK China has already:

  • Joined hands with the Home of Red Ribbon to combat HIV/AIDS, unveiling plan to support people living with HIV in Nov 2016.
  • Announced the strategic partnership with China Preventive Medicine Association (CPMA) to address major public health challenges in China in Nov 2016.
  • Announced the approval of Cervarix in China to help protect women from cervical cancer in July 2016.
  • Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.
  • Launched Tivicay, an innovative HIV drug, in June 2016.
  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.
  • Partnered with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Formalised a partnership with Shanghai-based Desano Pharmaceuticals to locally manufacture the Active Pharmaceutical Ingredient for Tivicay (dolutegravir) in July 2015.
  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.



GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit


GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.


GSK enquiries:

Susan Song            (Shanghai)


Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.